Cargando…
Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
Bladder cancer (BC) is one of the most prevalent malignancies worldwide and FGFR3 alterations are particularly common in BC. Despite approval of erdafitinib, durable responses for FGFR inhibitors are still uncommon and most patients relapse to metastatic disease. Given the necessity to discover more...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362036/ https://www.ncbi.nlm.nih.gov/pubmed/37479885 http://dx.doi.org/10.1038/s41698-023-00417-5 |